Based on those results, we speculated that the MSI subtype colon cancer patients were more easily induced into an immune activated status and were more sensitive to PD-1 blocking antibodies induced enhanced immunity to eliminate solid tumor cells. Here, PDCD1 is linked to malignant colon neoplasm.